Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib

Reviewer: Arpi Thukral, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 31 de mayo del 2008

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Alternate Chromosome 17 Genes Detect True HER2 Status

Sep 29, 2011

Three alternative chromosome 17 genes determine true HER2 status in breast cancer with polysomy 17

Dual Inhibition of HER2 Beats Single Agent in Breast Cancer

Jan 18, 2012

For HER2-positive breast cancer, inhibition with lapatinib and trastuzumab superior to single agent

Chemo, Trastuzumab, Surgery Up Survival in HER2-Positive MBC

Jul 19, 2011

After adjustment, only chemo, trastuzumab linked to survival for patients with CNS metastases